Quetiapine augmentation to serotonin reuptake inhibitors for patients with obsessive compulsive disorder: a double-blind, placebo-controlled study

niversity Medical Centre Utrecht (UMCU) (The Netherlands)0 个研究点目标入组 76 人开始时间: 2007年2月23日最近更新: 2021年7月26日

适应症

试验速览

2009 Results article in https://pubmed.ncbi.nlm.nih.gov/19497245/ (added 15/07/2021)

•1. All patients meet the Diagnostic and Statistical Manual of mental disorders fourth edition (DSM IV) criteria for obsessive-compulsive disorder
•2. Y-BOCS score more than 16 if obsessions and compulsions
•3. Y-BOCS score more than 10 if only obsessions
•4. Y-BOCS score more than 10 if only compulsions
•5. Male and female, aged between 18 and 70 years
•6. Female patients of childbearing potential must have a negative pregnancy test and use a reliable method of contraception
•7. Written informed consent

•1. Presence of any of the following DSM IV conditions:
•1.1. Major depression (with a Hamilton Depression Rating Scale [HDRS] more than 17 [17 item])
•1.2. Bipolar disorder
•1.3. Schizophrenia or any other psychotic condition
•1.4. Tic disorder, substance related disorder during the past six months
•1.5. Epilepsy, or any structural Central Nervous System (CNS) disorder or stroke within the last year
•2. Evidence of clinically significant and unstable cardiovascular, gastro-intestinal, pulmonary, renal, hepatic, endocrine or haematological disorders
•3. Glaucome, myocardial infarction within the past year, or micturition abnormalities
•4. Patients at risk for suicide
•5. Multiple serious drug allergies or known allergy for the trial compounds
•6. Use of antipsychotics during six months before the screening visit
•7. Cognitive and behavioural treatment three months prior to the screening visit
•8. Any known contra-indication against citalopram or quetiapine

发起方

niversity Medical Centre Utrecht (UMCU) (The Netherlands)